Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Assaf A. Barg"'
Autor:
Shadan Lalezari, Assaf A. Barg, Rima Dardik, Jacob Luboshitz, Dalia Bashari, Einat Avishai, Gili Kenet
Publikováno v:
TH Open, Vol 05, Iss 02, Pp e183-e187 (2021)
Aim Very little is known regarding reproductive choices, pregnancy, and delivery of women with moderate to severe hemophilia. Our aim was to describe our experience with three hemophiliac women and their journey to achieve motherhood. Methods Medical
Externí odkaz:
https://doaj.org/article/4483145807e0428c90908a643c4f5166
Publikováno v:
Thrombosis Update, Vol 7, Iss , Pp 100103- (2022)
Hemostasis is a dynamic process that starts in utero. Neonates, especially those who are born preterm, are at high risk of bleeding. The perinatal period is also associated with increased thrombosis risk as compared to older children. The coagulation
Externí odkaz:
https://doaj.org/article/46f5c8b3d7234108bca10af43e6a1654
Autor:
Omri Cohen, Orly Efros, Nicoletta Riva, Walter Ageno, Shelly Soffer, Eyal Klang, Assaf A. Barg, Gili Kenet, Sarina Levy-Mendelovich
Publikováno v:
Journal of Thrombosis and Haemostasis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb0a2aae945a6e0d56c5bba84592d046
https://doi.org/10.1016/j.jtha.2023.05.014
https://doi.org/10.1016/j.jtha.2023.05.014
Autor:
Assaf Arie Barg, Sarina Levy‐Mendelovich, Oded Gilad, Joanne Yacobovich, Ilia Tamarin, Ivan Budnik, Hana Golan, Amos Toren, Gili Kenet
Publikováno v:
Pediatric Blood & Cancer. 69
This is the first study examining real-life data of pediatric cancer patients treated with rivaroxaban. Children with thrombocytopenia and high bleeding risk were excluded from previous clinical trials. Data regarding the safety and efficacy of rivar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8cd79ca5c95c9f8c915c5f21e5699d3
https://doi.org/10.1002/pbc.29888
https://doi.org/10.1002/pbc.29888
Autor:
Omri Cohen, Kfir Lange, Ivan Budnik, Ilia Tamarin, Tami Brutman‐Barazani, Assaf Arie Barg, Nurit Rosenberg, Aharon Lubetsky, Gili Kenet, Sarina Levy‐Mendelovich
Publikováno v:
Pediatric bloodcancerREFERENCES. 69(11)
Heparin-induced thrombocytopenia (HIT) is rare among pediatric patients. The diagnosis of HIT depends upon clinical decision tools to assess its pretest probability, supported by laboratory evidence of anti-platelet factor 4 (anti-PF4)/heparin antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0025c31c97b48c489d9c25124b2d26
https://pubmed.ncbi.nlm.nih.gov/35997577
https://pubmed.ncbi.nlm.nih.gov/35997577
Autor:
Irtiza N. Sheikh, Lakshmi Srivaths, Emma Li, Orna Steinberg‐Shemer, Noa Mandel‐Shorer, Gili Kenet, Assaf A. Barg
Publikováno v:
Pediatric bloodcancerREFERENCES. 69(10)
In patients with inherited bleeding disorders, thrombus development poses a challenge in balancing the management of thrombosis and bleeding. Pediatric antithrombotic therapy guidelines do not address the treatment of a thrombus in the setting of a b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b51a3d458ed0552d0d3ad307253c2f6
https://pubmed.ncbi.nlm.nih.gov/35880957
https://pubmed.ncbi.nlm.nih.gov/35880957
Autor:
Assaf Arie Barg, Gili Kenet
Publikováno v:
Best practiceresearch. Clinical haematology. 35(1)
The etiology of pediatric cancer associated thrombosis (CAT) is multifactorial and may reflect pro-coagulant alterations of the hemostatic system induced by presence of cancer itself or by therapeutic chemotherapy, tumor mass effects, tumor thrombi,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2a9a49d1e5065ae392e0c38d0e2094
https://pubmed.ncbi.nlm.nih.gov/36030071
https://pubmed.ncbi.nlm.nih.gov/36030071
Autor:
D. Bashari, Einat Avishai, Tami Brutman-Barazani, Tami Livnat, Gili Kenet, Amir A. Kuperman, Mudi Misgav, Ivan Budnik, Assaf A. Barg, Aaron Lubetsky
Publikováno v:
Haemophilia. 27:383-391
Introduction Real-world data on prophylaxis of severe haemophilia A (HA) patients treated by emicizumab are scarce. Aim To study the efficacy and safety of longitudinal emicizumab prophylaxis and assess laboratory monitoring correlations in a large p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac461d3d569b848101cd3e2d280a777a
https://doi.org/10.1111/hae.14318
https://doi.org/10.1111/hae.14318
Publikováno v:
British Journal of Haematology. 201:597-597
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40c5af8cd6d85798bcd6a80004f61d90
https://doi.org/10.1111/bjh.18739
https://doi.org/10.1111/bjh.18739
Autor:
Gili Kenet, Einat Avishai, Ivan Budnik, Tami Brutman-Barazani, Jonathan Schapiro, Assaf A. Barg, Dalia Bashari, Mudi Misgav, A. Lubetsky, Tami Livnat
Publikováno v:
Haemophilia. 27:253-260
Introduction Emicizumab (Hemlibra™) is approved for prophylaxis of Haemophilia A (HA) patients with and without inhibitors. However, real-world data on emicizumab use in the elderly HA patients with concomitant cardiovascular risk factors are lacki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::165d4bec786c6a57c9791364601da456
https://doi.org/10.1111/hae.14261
https://doi.org/10.1111/hae.14261